Eventide Asset Management’s Praxis Precision Medicines PRAX Stock Holding History

Eventide Asset Management’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13M	Buy	38,684 +44	+0.1%	+$13.9K	0.17%	139
2026 Q1	$12.4M	Sell	38,640 -28,460	-42%	-$8.8M	0.21%	127
2025 Q4	$19.8M	Buy	+67,100	New	+$12.5M	0.31%	104
2023 Q1	–	Sell	-234,537	Closed	-$8.37M	–	158
2022 Q4	$8.37M	Hold	234,537	–	–	0.17%	114
2022 Q3	$7.99M	Hold	234,537	–	–	0.16%	109
2022 Q2	$8.62M	Sell	234,537 -58,463	-20%	-$6.24M	0.18%	102
2022 Q1	$44.9M	Buy	293,000 +38,960	+15%	+$8M	0.7%	46
2021 Q4	$75.1M	Hold	254,040	–	–	0.96%	37
2021 Q3	$70.5M	Buy	254,040 +1,570	+0.6%	+$426K	0.93%	37
2021 Q2	$67.7M	Buy	252,470 +18,265	+8%	+$6.54M	0.91%	41
2021 Q1	$109M	Hold	234,205	–	–	1.62%	15
2020 Q4	$184M	Buy	+234,205	New	+$137M	2.82%	6

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Eventide Asset Management's PRAX Position: Q2 2026 in Review

Eventide Asset Management increased its Praxis Precision Medicines (PRAX) stake by 0.11% in Q2 2026, buying an estimated $13.9K and bringing the position to 38,684 shares worth $13M. The position accounts for 0.17% of the portfolio, ranked #139.

Eventide Asset Management first reported a position in PRAX in Q4 2020 and has held it in 12 quarters since. The position peaked at $184M in Q4 2020. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Eventide Asset Management held 38,684 shares of Praxis Precision Medicines worth $13M as of Q2 2026.
Eventide Asset Management bought 44 Praxis Precision Medicines shares in Q2 2026, an estimated $13.9K.
Praxis Precision Medicines made up 0.17% of Eventide Asset Management's portfolio in Q2 2026, its #139 holding.
Eventide Asset Management first reported a position in Praxis Precision Medicines in Q4 2020 and has held it in 12 quarters since.
Eventide Asset Management's Praxis Precision Medicines position peaked at $184M in Q4 2020.
309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.